A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma.
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2013
At a glance
- Drugs IPH 1101 (Primary) ; Aldesleukin; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Mar 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
- 26 Jul 2011 New trial record